why choose us

First received: September 09, 2023

Clinical Trial: Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Post-transplant Lymphoproliferative Disorder

Study Type: INTERVENTIONAL


Official Title: A Phase I/II Study of Frontline Therapy With Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Brief Summary: This study will test polatuzumab vedotin in combination with rituximab in patients with treatment-naïve CD20-positive post-transplant lymphoproliferative disorder (PTLD) based on the established efficacy of polatuzumab vedotin in B-cell lymphomas and the inadequate response rate of PTLD to single-agent rituximab.The hypothesis is that this combination therapy will be safe, well-tolerated, and effective.If so, patients with PTLD will be able to be spared the toxicity of anthracycline-based…

Read more